COMMUNIQUÉS West-GlobeNewswire
-
Medigene AG to report full year 2023 financial results on March 28, 2024
18/03/2024 - 15:00 -
Novo Nordisk A/S - share repurchase programme
18/03/2024 - 15:18 -
Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21
18/03/2024 - 15:26 -
RS BioTherapeutics Selected for Presentation at American Thoracic Society’s 2024 Respiratory Innovation Summit
18/03/2024 - 16:30 -
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies
18/03/2024 - 11:00 -
Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress
18/03/2024 - 11:30 -
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
18/03/2024 - 11:30 -
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
18/03/2024 - 11:30 -
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 29 février 2024
18/03/2024 - 11:38 -
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
18/03/2024 - 11:50 -
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
18/03/2024 - 12:00 -
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
18/03/2024 - 12:00 -
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
18/03/2024 - 12:00 -
Sequel’s twiist™ Automated Insulin Delivery System Receives FDA 510(k) Clearance
18/03/2024 - 12:05 -
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
18/03/2024 - 12:05 -
Major shareholder announcement – Invesco Ltd.
18/03/2024 - 12:25 -
Major shareholder announcement – AIM International Mutual Funds
18/03/2024 - 12:28 -
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2
18/03/2024 - 12:28 -
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
18/03/2024 - 12:29
Pages